LAHORE: In a significant move to safeguard public health, the drug testing laboratories in Punjab have recently identified three medicines as substandard following rigorous impurity tests. This announcement has raised alarms across the pharmaceutical and healthcare sectors, prompting swift action from provincial authorities to prevent any potential health risks associated with these products.
The Punjab government has issued strict directives to all retailers, wholesalers, and distributors who currently stock these medicines. They have been instructed to immediately cease the sale and distribution of the identified drugs. Furthermore, these stakeholders are required to provide detailed reports to their respective area drug inspectors, outlining the current inventory levels as well as records of consumption. This measure aims to ensure transparency and facilitate the removal of these compromised medicines from the supply chain without delay.
The three medicines flagged for failing quality standards include: Sachet G-Mont 4 mg, produced by GT Pharma (Pvt.) Ltd; Film Coated Tablet Cetirizine Dihydrochloride 10 mg, manufactured by Pharman Pharmaceutical (Pvt.) Ltd; and Film Coated Tablet Bricit 10 mg, from British Pharmaceuticals. Each of these products was found to contain impurities beyond acceptable limits, which could potentially undermine their efficacy and safety for patients.
It is important to note that the identification of substandard medicines is part of ongoing efforts by Punjab’s drug regulatory authorities to maintain stringent quality control within the pharmaceutical market. Such inspections are crucial in a country where counterfeit and low-quality drugs pose serious health hazards. The provincial government’s proactive stance reflects its commitment to protecting consumers and upholding the integrity of healthcare services.
Meanwhile, healthcare professionals and consumers are advised to remain vigilant and avoid purchasing or using these specific medicines until further notice. Pharmacists and medical practitioners have been urged to inform their patients about the recall and to report any adverse effects linked to these products. The authorities continue to monitor the situation closely and are expected to take additional measures if necessary to ensure public safety.
